The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
The Quinolones: Past, Present, and Future
Abstract
The quinolone class of antimicrobial agents has generated considerable interest since its discovery >40 years ago. Substantial progress has been made in our understanding of the molecular mechanisms of the action of quinolones against pathogenic bacteria, the induction of resistance to quinolones in these organisms, and the potential of each quinolone compound to induce toxicity in treated patients. Here, these key discoveries are reviewed; the present indications approved by regulatory agencies are described in detail, with comments on adverse events caused by quinolones in treated patients; and speculation about the future of the quinolones is proffered, even though their future is difficult to predict, because many factors may affect their clinical usefulness. However, the emergence of bacterial resistance to the quinolones is a major factor that will determine the future clinical effectiveness of these agents, so that intense investigation of mechanisms to either prevent or curtail resistance to quinolones is of prime importance to their future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Blacklow, N. R., Gorbach, S. L., & Bartlett, J. G. (1992) · Cited by 2,753
DNA gyrase: an enzyme that introduces superhelical turns into DNA.
Gellert, M., Mizuuchi, K., O'Dea, M. H., & Nash, H. A. (1976) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.73.11.3872 · Cited by 1,204
Lomovskaya, O., Warren, M. S., Lee, A., Galazzo, J., Fronko, R., Lee, M., Blais, J., Cho, D., Chamberland, S., Renau, T., et al. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.1.105-116.2001 · Cited by 903
Nalidixic acid resistance: A second genetic character involved in DNA gyrase activity
Gellert, M., Mizuuchi, K., O'Dea, M. H., Itoh, T., & Tomizawa, J.-I. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.11.4772 · Cited by 833
Sugino, A., Peebles, C. L., Kreuzer, K. N., & Cozzarelli, N. R. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.11.4767 · Cited by 784
1,8-Naphthyridine Derivatives. A New Class of Chemotherapeutic Agents
Lesher, G. Y., Froelich, E. J., Gruett, M. D., Bailey, J. H., & Brundage, R. P. (1962) · Journal of Medicinal and Pharmaceutical Chemistry · doi:10.1021/jm01240a021 · Cited by 766
Structure-activity and structure-side-effect relationships for the quinolone antibacterials
Domagala, J. M. (1994) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/33.4.685 · Cited by 681
Resistance to Levofloxacin and Failure of Treatment of Pneumococcal Pneumonia
Davidson, R., Cavalcanti, R., Brunton, J. L., Bast, D. J., de Azavedo, J. C. S., Kibsey, P., Fleming, C., & Low, D. E. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012122 · Cited by 533
“Collateral Damage” from Cephalosporin or Quinolone Antibiotic Therapy
Paterson, D. L. (2004) · Clinical Infectious Diseases · doi:10.1086/382690 · Cited by 466
Antimicrobial Safety: Focus on Fluoroquinolones
Owens, R. C., & Ambrose, P. G. (2005) · Clinical Infectious Diseases · doi:10.1086/428055 · Cited by 415
Purification of subunits of Escherichia coli DNA gyrase and reconstitution of enzymatic activity
Higgins, N. P., Peebles, C. L., Sugino, A., & Cozzarelli, N. R. (1978) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.75.4.1773 · Cited by 257
DNA Gyrase and Topoisomerase IV Are Dual Targets of Clinafloxacin Action in Streptococcus pneumoniae
Pan, X.-S., & Fisher, L. M. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.11.2810 · Cited by 215
DNA topoisomerase targets of the fluoroquinolones: A strategy for avoiding bacterial resistance
Zhao, X., Xu, C., Domagala, J., & Drlica, K. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.25.13991 · Cited by 213
Oethinger, M., Kern, W. V., Jellen-Ritter, A. S., McMurry, L. M., & Levy, S. B. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.1.10-13.2000 · Cited by 213
Inhibition of efflux pumps as a novel approach to combat drug resistance in bacteria.
Lomovskaya, O., & Watkins, W. (2001) · PubMed · Cited by 161
Jones, M. E., Sahm, D. F., Martin, N., Scheuring, S., Heisig, P., Thornsberry, C., Köhrer, K., & Schmitz, F.-J. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.2.462-466.2000 · Cited by 158
Seral, C. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg223 · Cited by 115
Fluoroquinolone‐ResistantStreptococcus pneumoniaeAssociated with Levofloxacin Therapy
Urban, C. M., Rahman, N. A., Zhao, X., Mariano, N., Segal‐Maurer, S., Drlica, K., & Rahal, J. J. (2001) · The Journal of Infectious Diseases · doi:10.1086/323086 · Cited by 110
Chemistry and Mechanisms of Action of the Quinolone Antibacterials
Smith, J. T., & Lewin, C. S. (1988) · Elsevier eBooks · doi:10.1016/b978-0-12-059515-0.50006-8 · Cited by 103
Andriole, V. T. (1999) · Drugs · doi:10.2165/00003495-199958002-00001 · Cited by 99
Self-citationPiddock, L. J. V., Johnson, M. M., Ricci, V., & Hill, S. L. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.11.2956 · Cited by 95
González, I., Georgiou, M., Alcaide, F., Balas, D., Liñares, J., & de la Campa, A. G. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.11.2792 · Cited by 94
Kays, M. B., Smith, D. W., Wack, M. F., & Denys, G. A. (2002) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.22.5.395.33185 · Cited by 93
Levofloxacin Failure in a Patient with Pneumococcal Pneumonia
Empey, P. E., Jennings, H. R., Thornton, A., Rapp, R. P., & Evans, M. E. (2001) · Annals of Pharmacotherapy · doi:10.1345/aph.10229 · Cited by 87
Nakayama, K., Ishida, Y., Ohtsuka, M., Kawato, H. C., Yoshida, K., Yokomizo, Y., Hosono, S., Ohta, T., Hoshino, K., Ishida, H., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.07.024 · Cited by 86
Baucheron, S. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh122 · Cited by 82
Watkins, W. J., Landaverry, Y. R., Léger, R., Litman, R., Renau, T. E., Williams, N., Yen, R., Zhang, J. Z., Chamberland, S., Madsen, D., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.07.030 · Cited by 78
Efflux in bacteria: what do we really know about it?
Ryan, B., Dougherty, T. J., Beaulieu, D., Chuang, J., Dougherty, B. A., & Barrett, J. F. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.8.1409 · Cited by 76
Nakayama, K., Kuru, N., Ohtsuka, M., Yokomizo, Y., Sakamoto, A., Kawato, H. C., Yoshida, K., Ohta, T., Hoshino, K., Akimoto, K., et al. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2004.03.007 · Cited by 51
Quinolone Resistance Mechanisms in Pneumococci
Eliopoulos, G. M. (2004) · Clinical Infectious Diseases · doi:10.1086/382709 · Cited by 49
The Continuing Challenge of Lower Respiratory Tract Infections
Moellering, R. C. (2004) · Clinical Infectious Diseases · doi:10.1086/382685 · Cited by 25
Treatment of Respiratory Infections with Quinolones
Iannini, P. B., Niederman, M. S., & Andriole, V. T. (2000) · Elsevier eBooks · doi:10.1016/b978-012059517-4/50009-x · Cited by 11
Self-citationUse of the Quinolones for Treatment and Prophylaxis of Bacterial Gastrointestinal Infections
Hamer, D. H., & Gorbach, S. L. (2000) · Elsevier eBooks · doi:10.1016/b978-012059517-4/50011-8 · Cited by 10
Use of the Quinolones in Skin and Skin Structure (Osteomyelitis) and Other Infections
Karchmer, A. W. (2000) · Elsevier eBooks · doi:10.1016/b978-012059517-4/50014-3 · Cited by 5
Cited by
Mechanism of Quinolone Action and Resistance
Aldred, K. J., Kerns, R. J., & Osheroff, N. (2014) · Biochemistry · doi:10.1021/bi5000564 · Cited by 1,282
Best Practice Policy Statement on Urologic Surgery Antimicrobial Prophylaxis
Wolf, J. S., Bennett, C. J., Dmochowski, R. R., Hollenbeck, B. K., Pearle, M. S., & Schaeffer, A. J. (2008) · Journal of Urology · doi:10.1016/j.juro.2008.01.068 · Cited by 901
Antibiotic resistance in Staphylococcus aureus. Current status and future prospects
Foster, T. J. (2017) · FEMS Microbiology Reviews · doi:10.1093/femsre/fux007 · Cited by 845
Non-inherited antibiotic resistance
Levin, B. R., & Rozen, D. E. (2006) · Nature Reviews Microbiology · doi:10.1038/nrmicro1445 · Cited by 542
Quinolones: Mechanism, Lethality and Their Contributions to Antibiotic Resistance
Bush, N. G., Diez-Santos, I., Abbott, L. R., & Maxwell, A. (2020) · Molecules · doi:10.3390/molecules25235662 · Cited by 413
Metadata
- Authors
- Andriole, V. T.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-07-15
- Volume
- 41
- Issue
- Supplement_2
- Pages
- S113-S119
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2070600380
- Cited by
- 428
- References
- 34
- FWCI
- 2.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.